Sangmin Lee
Hematology & Oncology · New York, NYNPI 1144423237
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,186 of the $28,908 with a category attached, or 73.3%. 14 manufacturers reported payments, led by Helsinn Healthcare SA at 31.0% of the total. Reporting peaked in 2019 at $24,936 and has fallen 99.8% since, to $39 in 2025.
Across 49 payments — averaging $589.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Helsinn Healthcare SA$9K
- AstraZeneca$9K
- Jazz Pharmaceuticals Inc.$7K
- Bristol Myers Squibb$2K
- AbbVie$2K
- Roche Molecular Systems, Inc.$400
- plus $462 from 8 others
Across 20 payments — averaging $52,045 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stemline Therapeutics Inc.$559K
- Acerta Pharma LLC$256K
- Orphai Therapeutics Inc.$139K
- Janssen Research & Development, LLC$76K
- Helsinn Healthcare SA$10K
- Novartis$404
What the payments were for
- Consulting fees$21,18673%
- Speaking & faculty fees$4001%
- Travel & lodging$6,48722%
- Food & beverage$8343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Helsinn Healthcare SA | 5 | $8,957 |
| AstraZeneca | 7 | $8,573 |
| Jazz Pharmaceuticals Inc. | 8 | $6,565 |
| Bristol Myers Squibb | 3 | $2,300 |
| AbbVie | 1 | $1,650 |
| Roche Molecular Systems, Inc. | 1 | $400 |
| Pfizer | 15 | $200 |
| Stemline Therapeutics Inc. | 1 | $92 |
| Janssen Global Services, LLC | 1 | $39 |
| Johnson & Johnson | 1 | $33 |
| Novartis | 2 | $32 |
| Dova Pharmaceuticals | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMOXITI$7,770
- Reblozyl$2,260
- Venclexta$1,650
- DIAGNOSTICS INFORMATION SYSTEMS$400
How this compares
$28,908 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.